Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone

Chih Jung Yao, Gi Ming Lai, Chin Feng Chan, Ann L. Cheng, Ya Y. Yang, Shuang E. Chuang

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Lovastatin (an HMG-CoA reductase inhibitor) and troglitazone (a PPAR-γ agonist) have been intensively studied prospectively for their application in cancer treatment. However, clinical trials of lovastatin or troglitazone in cancer treatment resulted in only limited responses. To improve their efficacy, lovastatin and troglitazone have, respectively, been tried to combine with other anticancer agents with varied outcomes. In our study, we found a dramatic synergism between lovastatin and troglitazone in anticancer at clinically achievable concentrations. This synergism was found in far majority of cell lines tested including DBTRG 05 MG (glioblastoma) and CL1-0 (lung). This amazing synergism was accompanied by synergistic modulation of E2F-1 and p27Kip1, which were reported to mediate the anticancer activities of lovastatin and troglitazone, respectively, and other cell cycle regulating proteins such as CDK2, cyclin A and RB phosphorylation status. With this dramatic combination effect of lovastatin and troglitazone, a promising regimen of cancer therapy may be materialized in the future.

Original languageEnglish
Pages (from-to)773-779
Number of pages7
JournalInternational Journal of Cancer
Volume118
Issue number3
DOIs
Publication statusPublished - Mar 1 2006
Externally publishedYes

Fingerprint

troglitazone
Lovastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cyclin A
Neoplasms
Cell Cycle Proteins
Peroxisome Proliferator-Activated Receptors
Glioblastoma
Antineoplastic Agents
Phosphorylation
Clinical Trials

Keywords

  • HMG-CoA reductase
  • Lovastatin
  • PPAR-gamma
  • Statin
  • Synergism
  • Troglitazone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. / Yao, Chih Jung; Lai, Gi Ming; Chan, Chin Feng; Cheng, Ann L.; Yang, Ya Y.; Chuang, Shuang E.

In: International Journal of Cancer, Vol. 118, No. 3, 01.03.2006, p. 773-779.

Research output: Contribution to journalArticle

Yao, Chih Jung ; Lai, Gi Ming ; Chan, Chin Feng ; Cheng, Ann L. ; Yang, Ya Y. ; Chuang, Shuang E. / Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. In: International Journal of Cancer. 2006 ; Vol. 118, No. 3. pp. 773-779.
@article{be651bb5a0694b9faa7fb95f444d9df4,
title = "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone",
abstract = "Lovastatin (an HMG-CoA reductase inhibitor) and troglitazone (a PPAR-γ agonist) have been intensively studied prospectively for their application in cancer treatment. However, clinical trials of lovastatin or troglitazone in cancer treatment resulted in only limited responses. To improve their efficacy, lovastatin and troglitazone have, respectively, been tried to combine with other anticancer agents with varied outcomes. In our study, we found a dramatic synergism between lovastatin and troglitazone in anticancer at clinically achievable concentrations. This synergism was found in far majority of cell lines tested including DBTRG 05 MG (glioblastoma) and CL1-0 (lung). This amazing synergism was accompanied by synergistic modulation of E2F-1 and p27Kip1, which were reported to mediate the anticancer activities of lovastatin and troglitazone, respectively, and other cell cycle regulating proteins such as CDK2, cyclin A and RB phosphorylation status. With this dramatic combination effect of lovastatin and troglitazone, a promising regimen of cancer therapy may be materialized in the future.",
keywords = "HMG-CoA reductase, Lovastatin, PPAR-gamma, Statin, Synergism, Troglitazone",
author = "Yao, {Chih Jung} and Lai, {Gi Ming} and Chan, {Chin Feng} and Cheng, {Ann L.} and Yang, {Ya Y.} and Chuang, {Shuang E.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/ijc.21361",
language = "English",
volume = "118",
pages = "773--779",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone

AU - Yao, Chih Jung

AU - Lai, Gi Ming

AU - Chan, Chin Feng

AU - Cheng, Ann L.

AU - Yang, Ya Y.

AU - Chuang, Shuang E.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Lovastatin (an HMG-CoA reductase inhibitor) and troglitazone (a PPAR-γ agonist) have been intensively studied prospectively for their application in cancer treatment. However, clinical trials of lovastatin or troglitazone in cancer treatment resulted in only limited responses. To improve their efficacy, lovastatin and troglitazone have, respectively, been tried to combine with other anticancer agents with varied outcomes. In our study, we found a dramatic synergism between lovastatin and troglitazone in anticancer at clinically achievable concentrations. This synergism was found in far majority of cell lines tested including DBTRG 05 MG (glioblastoma) and CL1-0 (lung). This amazing synergism was accompanied by synergistic modulation of E2F-1 and p27Kip1, which were reported to mediate the anticancer activities of lovastatin and troglitazone, respectively, and other cell cycle regulating proteins such as CDK2, cyclin A and RB phosphorylation status. With this dramatic combination effect of lovastatin and troglitazone, a promising regimen of cancer therapy may be materialized in the future.

AB - Lovastatin (an HMG-CoA reductase inhibitor) and troglitazone (a PPAR-γ agonist) have been intensively studied prospectively for their application in cancer treatment. However, clinical trials of lovastatin or troglitazone in cancer treatment resulted in only limited responses. To improve their efficacy, lovastatin and troglitazone have, respectively, been tried to combine with other anticancer agents with varied outcomes. In our study, we found a dramatic synergism between lovastatin and troglitazone in anticancer at clinically achievable concentrations. This synergism was found in far majority of cell lines tested including DBTRG 05 MG (glioblastoma) and CL1-0 (lung). This amazing synergism was accompanied by synergistic modulation of E2F-1 and p27Kip1, which were reported to mediate the anticancer activities of lovastatin and troglitazone, respectively, and other cell cycle regulating proteins such as CDK2, cyclin A and RB phosphorylation status. With this dramatic combination effect of lovastatin and troglitazone, a promising regimen of cancer therapy may be materialized in the future.

KW - HMG-CoA reductase

KW - Lovastatin

KW - PPAR-gamma

KW - Statin

KW - Synergism

KW - Troglitazone

UR - http://www.scopus.com/inward/record.url?scp=30444453243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444453243&partnerID=8YFLogxK

U2 - 10.1002/ijc.21361

DO - 10.1002/ijc.21361

M3 - Article

C2 - 16094629

AN - SCOPUS:30444453243

VL - 118

SP - 773

EP - 779

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -